Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Tax Provisions (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Tax Provisions readings, the most recent being $313000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 9.44% year-over-year to $313000.0, compared with a TTM value of $1.8 million through Dec 2025, up 48.9%, and an annual FY2025 reading of $1.7 million, up 48.19% over the prior year.
  • Tax Provisions hit $313000.0 in Q4 2025 for Apellis Pharmaceuticals, down from $600000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $1.4 million in Q4 2023, with the low at -$1.5 million in Q4 2022.
  • Median Tax Provisions over the past 5 years was $341000.0 (2025), compared with a mean of $357941.2.
  • The sharpest move saw Tax Provisions plummeted 517.9% in 2022, then skyrocketed 400.0% in 2025.
  • Year by year, Tax Provisions stood at $352000.0 in 2021, then crashed by 517.9% to -$1.5 million in 2022, then soared by 197.35% to $1.4 million in 2023, then crashed by 80.03% to $286000.0 in 2024, then grew by 9.44% to $313000.0 in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $313000.0, $600000.0, and $500000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.